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Atypical adenomatous hyperplazia (AAH) is a localised prolifera-
tion of alveolar lining cells, found particularly in the centriacinar
regions of the peripheral alveolated lung. It has recently been a
focus of attention after Miller et al (1988) suggested this lesion
may be the adenoma in an adenoma–carcinoma sequence in the
lung periphery, leading to the development of adenocarcinoma.
This was based largely on the association of AAH lesions with
peripheral type adenocarcinoma of the lung, a tumour classified as
bronchioloalveolar carcinoma (BAC) and invasive adenocarci-
noma with bronchioloalveolar features in the new WHO lung
tumour classification (Travis et al, 1999). As well as the morpho-
logical similarity between large atypical AAH lesions and BAC,
epidemiological data (Miller, 1990), morphometric and flow cyto-
metric DNA analysis (Kodama et al, 1986; Nakayama et al, 1990;
Mori et al, 1993), and molecular biological evidence particularly,
including abnormal oncogene and tumour suppressor gene expres-
sion (Kerr et al, 1994; Hayashi et al, 1997; Kurasono et al, 1998),
in addition to evidence of K-ras mutation (Westra et al, 1996;
Cooper et al, 1997), have provided evidence to support this
hypothesis. Recent data have shown that AAH lesions are clonal
(Niho et al, 1999).
The identification of a potential precursor lesion for peripheral
adenocarcinoma is of particular interest since the origin of this
type of tumour was previously unknown, unlike the well known
origin of central bronchogenic squamous carcinoma from
bronchial squamous dysplasia/carcinoma-in-situ. Furthermore,
there is evidence that adenocarcinoma is increasing in incidence in
the Western world while squamous carcinoma incidence may be
falling (Travis et al, 1995). These findings in the USA have been
mirrored in the UK (Connolly et al, 1997) and in our own studies
in NE Scotland (Kerr et al, 1996). Scotland has one of the highest
lung cancer rates, in both males and females, in the world (Sharp
and Brewster, 1999). Adenocarcinoma has long been the
commonest form of lung cancer in Japan and in other Oriental
populations (Shimosato et al, 1982) and it is notable that almost all
of the literature on the subject of AAH concerns Japanese patients.
In this paper we present data on the association of AAH with
lung cancer from a Scottish population and examine the influence
of the presence of AAH on patient survival.
MATERIALS AND METHODS
From 1989 to 1998 inclusive, we undertook a systematic prospec-
tive search for AAH in pulmonary resection specimens received in
our department. Lung specimens were inflated perbronchially with
4% neutral buffered formal saline and allowed to fix in a reservoir
of formalin for at least 24 hours. The specimens were sliced
parasagittally at 1 cm thick intervals and carefully examined for
AAH lesions, in addition to assessment of the main lesion for
which the resection was performed. AAH lesions are often diffi-
cult to identify macroscopically due to their small size but can
sometimes be identified as small yellow or grey foci, a few
millimetres in diameter, on the cut surface of the lung. More often,
however, they are found by chance on random sampling of the
lung parenchyma, so that all foci suggestive of AAH were sampled
and/or usually 1–6 random blocks of lung parenchyma were taken
and examined histologically. The typical histological appearances
of AAH are shown in Figure 1 with, for comparison, a BAC and
invasive adenocarcinoma. AAH is characterized by alveoli lined
by an often intermittent layer of cuboidal or low columnar cells
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Mitoses are very rare and the alveolar walls are slightly thickened
by variable amounts of collagen and fibroblasts. As AAH becomes
more cellular and atypical, distinction from bronchioloalveolar
carcinoma (a non-invasive lesion by the WHO definition) (Travis
et al, 1999) may be difficult but the latter diagnosis is used in cases
of larger lesions, usually over 1 cm where there is a complete
lining of all the alveoli by a compact columnar cell population
showing more atypia, close cell–cell apposition and a sharp
distinction between the lesion and surrounding lung. The cells in
BAC comprise a more homogeneous population than that usually
seen in AAH. Similar features help distinguish AAH from a
possible intrapulmonary metastasis from the associated primary
tumour. Here the degree of cellular pleomorphism and greater cell
size is the rule in a metastasis. In practice this latter distinction is
virtually never an issue. The age and sex of each patient with AAH
was noted and compared with data on patients without AAH. The
histological type of the main cancer, the number of AAH lesions in
each resection specimen and the number and type of any additional
tumours were recorded for each patient with AAH. The local
Cancer Registry provided information on whether or not the
patients remained alive on the study date in February 1999. This
information was used to compare postoperative survival in lung
cancer patients with and without AAH, using the Kaplan-Meier
method.
RESULTS
From a total of 582 patients, 70 were found to have AAH (12%)
(in specimens comprising 42 lobectomies, 22 pneumonectomies
and 6 segmental/wedge resections). The age range for the patients
with AAH was 36–84 years (mean age 62 years), almost identical
to that for the entire study group (mean age 63 years). From the
whole group, 554 patients (391 males and 163 females) had
primary carcinoma of lung and of these, 138 males (35.3%) and 86
females (52.7%) had adenocarcinoma. Of the patients with AAH,
37 were male and 33 were female. Sixty-seven of the 70 patients
with AAH underwent lung resection for primary lung cancer.
Three patients, two females and one male, each with a single AAH
lesion, had surgery for other tumours (metastatic sarcoma,
metastatic rectal carcinoma and solitary fibrous tumour of pleura).
Thus AAH was found in 12.1% of lungs bearing primary lung
cancer (9.2% in male patients and 19.0% in females).
Fifty-two of the 67 patients with primary lung cancer and AAH
had surgery for primary adenocarcinoma. AAH was found in
23.2% of adenocarcinoma bearing lungs but less often in those
with large cell or squamous cell carcinoma (12.5% and 3.3%
respectively) (Table 1). AAH was present in 30.2% of females, but
in only 18.8% of males with adenocarcinoma.
The number of AAH lesions found in each resection specimen
ranged from 1–42 (Table 2). Two thirds of the cases had 2 or more
lesions, while 17% had 6 or more. Four patients had large
numbers–12, 19, 34 and 42 lesions respectively, per patient. All
patients with 6 or more AAH lesions had adenocarcinoma, except
one who had a mixed tumour that included adenocarcinoma.
Ten of the 67 patients with primary lung carcinoma had multiple
(2–6) cancers (15%) (including the 3 patients with most AAH
lesions) and in all cases, the main primary and synchronous
tumours were adenocarcinoma, the additional cancers usually
being small (T1) tumours (Table 3).
Despite an apparent trend to better survival in the AAH group,
there was no statistical difference in post-operative survival
between those 70 patients with AAH and the remaining 512
patients whose resection specimens showed no evidence of AAH
(P = 0.21, Figure 2). The findings were the same when only
patients with Stage I tumours were considered.
DISCUSSION
In this prospective study of 582 patients, the incidence of AAH in
the 554 lungs resected for primary lung cancer is at least 12.1%
and is particularly strongly associated with primary adenocarci-
noma (23.2%). Also, patients with adenocarcinoma are more
AAH and lung cancer 633
British Journal of Cancer (2000) 83(5), 632–636 © 2000 Cancer Research Campaign
A
B
C
Figure 1 (H&E, × 100). (A) Low grade atypical adenomatous hyperplasia.
(B) Bronchioloalveolar carcinoma. Tumour cells line alveolar walls but there
is no evidence of stromal invasion. (C) Invasive adenocarcinoma. Bar
represents 200 µ mlikely to have larger numbers of AAH lesions when compared to
those with other cancer types.
Our similar numbers of males and females with AAH contrasts
with our previous report on 10 AAH patients, 7 of whom were
women (Carey et al, 1992). In two Japanese studies, 11 of 15
(Nakanishi, 1990) and 22 of 27 (Weng et al, 1992) patients,
respectively, were men, probably reflecting the greater frequency
of lung cancer in males. Our greater frequency of AAH in women
(19.0% of lung cancer resections, 30.2% of those specifically with
adenocarcinoma) when compared to men (9.2% and 18.8%
respectively) is interesting and contrasts with the study by Weng et
al (1992), where 20% of the male, but only 4.8% of the female
lung cancer patients had AAH. Why Scottish women should show
a greater tendency to develop AAH, when compared to Japanese
women, is not clear. Comparisons are difficult between cultural
groups. Even though adenocarcinoma is proportionately more
common in females, women with adenocarcinoma still have more
AAH than do men with with adenocarcinoma.
In the only other published non-Japanese study, from
Vancouver, AAH was found in 9.3% of 247 lungs bearing a
primary cancer (Miller, 1990). In four Japanese studies AAH was
found in 12.2%, 13.9%, 16.4% and 21.4% of 131, 203, 210 and 70
resected lungs respectively (Morinaga and Shimosato, 1987;
Kodama et al, 1988; Nakanishi, 1990; Weng et al, 1992). Noguchi
and Shimosato (1995) reported AAH in 5.1% of 2098 cases but
data were gathered from records spanning 1965–1989 and were
not, apparently, the result of a prospective search for AAH. This
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Table 1 Number of patients with AAH in relation to histological type of main tumour
Histological type of main tumour Number of Number of patients with
patients (n = 582) AAH (n = 70) (%)
Adenocarcinoma 224 52 (23.2)
Large cell carcinoma 24 3 (12.5)
Squamous cell carcinoma 214 7 (3.3)
Other primary carcinomas 92 5 (5.4)
Other primary malignancy 8 0
Metastatic disease 15 2 (13.3)
Benign tumours 5 1 (20)
Table 2 Number of AAH lesions per case and comparison with published studies
Total 1 AAH per 2 lesions 3–5 lesions 6–8 lesions ≥ 9 lesions
patients case per case per case per case per case
with AAH
No. of patients 70 24 17 17 8 4
(Current study)
No. of patients 27 15 5 5 1 1
(Weng et al, 1992)
No. of patients 15 9 1 4 1
(Nakanishi, 1990)
No. of patients 28 14 4 5 5
(Miller, 1990)
Table 3 Patients with AAH and multiple primary adenocarcinomas
Patient Number of Number of cancers
AAH in specimena
14 2 6
23 4 3
31 9 3
484
552
622
713
8, 9, 10 1 2
a All of these tumours were adenocarcinomas, of varying types according to
the WHO classification (Travis et al, 1999). Many were invasive well
differentiated adenocarcinoma with bronchioloalveolar features, especially
the small additional cancers, while some were poorly differentiated.
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Figure 2 Kaplan-Meier survival curves for patients with and without AAH.
No significant difference exists between the two curves (P = 0.21)AAH and lung cancer 635
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variation in published figures for AAH incidence is partly due to
differences in sampling techniques used. It is clear that all studies
will underestimate the number of lesions present and that the
harder one looks, the more will be found.
AAH is less often found in lungs without a primary carcinoma.
Two studies found AAH in, respectively, 4.4% and 9.6% of resec-
tions without primary carcinoma (Morinaga and Shimosato, 1987;
Weng et al, 1992). We found AAH in 10.7% of such cases but our
numbers are small. In a prospective autopsy study of 100 consecu-
tive cases, only 2 patients were found to have AAH (Sterner et al,
1997). Neither had lung cancer. It is not clear what the incidence of
AAH is in those without primary lung cancer, but it is lower than
in those with the disease.
AAH is most common in lungs bearing adenocarcinoma. Our
finding of AAH in 23.2% of such cases compares with 15.6%,
18.8%, 19.2%, 25.5% and 35.5%, respectively, in other series
(Morinaga and Shimosato, 1987; Kodama et al, 1988; Miller,
1990; Nakanishi, 1990; Weng et al, 1992). The figures for squa-
mous carcinoma bearing lungs are smaller: our figure of 3.3% is
similar to the 3.0%, 5.9%, 6.9%, 9.4% and 11.1% of others
(Morinaga and Shimosato, 1987; Kodama et al, 1988; Miller,
1990; Nakanishi, 1990; Weng et al, 1992). The relatively high
frequency of AAH associated with large cell undifferentiated
carcinoma is notable – 12.5% in our series versus 10% and 25% in
the literature (Nakanishi, 1990; Weng et al, 1992) – particularly
since there is some evidence from ultrastructural studies that most
large cell undifferentiated carcinomas show adenocarcinomatous
differentiation (Hammar, 1993). Central bronchial squamous
carcinomas are more likely to show distal obstructive pneumonitis
than peripheral adenocarcinomas, which will reduce the numbers
of AAH found. Nonetheless, the association with adenocarcinoma
does appear real.
AAH numbers per case vary. More patients have relatively few
AAH lesions, a smaller number have several (Table 2). Other
published studies concur with this trend but, like Miller (1990), we
have a notable number of patients with many AAH foci. Miller’s
original proposal of this adenoma–carcinoma sequence came from
the observation that adenocarcinoma is not infrequently multi-
centric and that larger numbers of AAH lesions are found in
adenocarcinoma bearing lungs (Miller et al, 1988; Miller, 1990).
Our ten patients with multiple adenocarcinomas associated with
often large numbers of AAH lesions (Table 3) provide more
evidence for the relationship between AAH and adenocarcinoma.
Only 5 other patients are reported with multiple cancers, almost
always adenocarcinoma, and multiple AAH (Nakanishi, 1990;
Weng et al, 1990; Anami et al, 1998; Suzuki et al, 1998a). That
15% of our lung cancer patients with AAH have multiple synchro-
nous primary tumours is interesting. Multiple primary malignancy
is found in up to 2% of most reported series of resected tumours
(Carey et al, 1993), including ours, when AAH cases are excluded.
Two of our patients with AAH and adenocarcinoma had a second
(metachronous) lung cancer, one of which was also adenocarci-
noma. In all our cases where there were multiple adenocarci-
nomas, there was clear morphological evidence that these were not
metastases from the main lesion. We found no difference in post-
operative survival between those patients with and without AAH,
both overall and for Stage I disease only. This is a similar finding
to the work of Suzuki et al (1997). Takigawa et al (1999), however,
suggested that patients with stage IA adenocarcinoma and AAH
may have a better prognosis than those with the same cancer but
no AAH, though this difference did not reach statistical signifi-
cance.
This study provides evidence of a strong association between
AAH and adenocarcinoma in the lung in a Western Caucasian
population, similar to the experience in Japan. These data underpin
the proposed AAH/adenoma–carcinoma sequence in the lung, a
concept further strengthened by various immunohistochemical and
molecular biological studies (Kitamura et al, 1999; Kerr, 2000).
The finding of multiple AAH lesions in patients with multiple lung
cancers, together with the report of AAH in a patient with multiple
synchronous lung cancers in Li-Fraumeni syndrome (Nadav et al,
1998) and multiple AAH lesions associated with tumours which
have deletions in the tuberous sclerosis complex (TSC-1) region
on 9 q (Suzuki et al, 1998b), raises interesting questions about
possible underlying genetic abnormalities in this disease. The idea
that multiple AAH may represent a form of ‘field cancerization’ in
the lung periphery is also an attractive one, similar to the wide-
spread genotypic changes which parallel the multifocal phenotypic
changes seen in the bronchial epithelium in many tobacco smokers
(Wistuba et al, 1999). Niho et al (1999) have demonstrated mono-
clonality in AAH with clonal heterogeneity between multiple
AAH lesions from the same patient. This multifocal ‘field’ effect
is supported by some similar studies on BAC (Barsky et al, 1994),
but not by others (Holst et al, 1998). The survival studies are an
inadequate tool to determine much about the natural history of
AAH lesions since patient outcome will be determined to a greater
extent by the intercurrent cancer present in almost all patients.
Until we have more patients with AAH, but without cancer, for
extended follow-up or are even able to observe AAH longitudi-
nally in a patient over a long time period, detail of the natural
history of AAH will remain elusive. The rising incidence of
primary lung adenocarcinoma in Western countries, together with
the increase in lung cancer in women (who develop more adenocar-
cinoma than men and who seem, at least in Scotland, to be more
likely to develop AAH) highlight the need for greater awareness of
the precursor of this disease. This is particularly true if any progress
is to be made with screening for this common fatal malignancy.
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